COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

Stylianos A KandarakisAlexandros P PapadopoulosGeorgios RoussopoulosEustathios GeorgopoulosYoungsik ChungLeonidas DoumazosAreum BaekNefeli Ioanna PaiziHyunik ShinPantelis A Papadopoulos

Published in: Expert opinion on drug safety (2023)

YSLT eye drops demonstrated non-inferiority to latanoprost in reducing IOP. Both products were well tolerated without serious TEAEs reported.

Keyphrases

phase iii
clinical trial
open label
double blind
phase ii
placebo controlled
blood pressure
drug delivery
study protocol
drug induced